Loading...
Loading...
ANL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.6M |
| Gross Profit | -0.6M |
| Operating Expense | 16.9M |
| Operating I/L | -16.9M |
| Other Income/Expense | -46.5M |
| Interest Income | 0.2M |
| Pretax | -63.4M |
| Income Tax Expense | -46.2M |
| Net Income/Loss | -63.4M |
Adlai Nortye Ltd. is a clinical-stage biotechnology company specializing in the discovery and development of cancer therapies. Its lead product, AN2025, is a pan-phosphoinositide 3-kinase inhibitor currently in Phase III clinical trial for recurrent or metastatic head and neck squamous cell carcinomas. The company also focuses on developing AN0025, a small molecule EP4 antagonist, and AN4005, an oral small-molecule PD-L1 inhibitor. Additionally, its preclinical candidates include AN8025, AN1025, and AN9025, targeting various cancer-related pathways. Adlai Nortye generates revenue through the research, development, and potential commercialization of these innovative cancer therapies.
